- Conditions
- Head and Neck Cancer
- Interventions
- amifostine trihydrate, cisplatin, fluorouracil, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 17,105
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • San Francisco, California • Miami, Florida + 9 more
- Conditions
- Liver Diseases, Portal Hypertension
- Interventions
- SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, End-Stage Renal Disease
- Interventions
- Specialized Community Disease Management, Treatment As Usual
- Behavioral
- Lead sponsor
- Treatment Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Genetic Disease
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 100 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2099
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 21 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- itacitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
- Conditions
- Knee Osteoarthritis, PJI
- Interventions
- Next Generation Sequencing
- Diagnostic Test
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Complex Regional Pain Syndrome (CRPS)
- Interventions
- Neridronic acid 100 mg, Placebo
- Drug
- Lead sponsor
- Grünenthal GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more
- Conditions
- Polyethylene Glycols, Children, Only
- Interventions
- PEG 3350
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 16 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Gamification plus social incentive, Gamification plus competition
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sarcoma
- Interventions
- CivaSheet
- Device
- Lead sponsor
- CivaTech Oncology
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- [F18]CP-18 Injection
- Radiation
- Lead sponsor
- Siemens Molecular Imaging
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Irvine, California • Los Angeles, California • Philadelphia, Pennsylvania
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- adjuvant therapy, paclitaxel, carboplatin, bevacizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 17
- States / cities
- Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more
- Conditions
- Defibrillators, Implantable, Tachycardia, Ventricular
- Interventions
- Ablation, Amiodarone
- Procedure · Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 19 Years to 84 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Philadelphia, Pennsylvania + 2 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
- Conditions
- Dehydration in Children, Fluid Therapy
- Interventions
- Urinalysis (UA), Complete Metabolic Panel (CMP), Glucose Stick Test (d-Stick), Medical Chart Review
- Diagnostic Test · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
- Interventions
- Dapagliflozin 10 mg, Placebo tablet
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 17,190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 234
- States / cities
- Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more
- Conditions
- Acromegaly
- Interventions
- Octreotide capsules
- Drug
- Lead sponsor
- Chiasma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
- Conditions
- Hormone Deficiency, Aging
- Interventions
- Growth Hormone Releasing Hormone (GHRH )
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 42 more
- Conditions
- Skin Cancer Face, Quality of Life, Surgical Wound, Peer Mentorship
- Interventions
- Peer Mentorship Program
- Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 82
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
- Conditions
- Atopic Dermatitis
- Interventions
- PF-07275315, PF-07264660, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 42 more